Literature DB >> 16686435

A central role for oxygen-sensitive K+ channels and mitochondria in the specialized oxygen-sensing system.

Stephen L Archer1, Evangelos D Michelakis, Bernard Thébaud, Sebastien Bonnet, Rohit Moudgil, Xi-Chen Wu, E Kenneth Weir.   

Abstract

Mammals possess a specialized O2-sensing system (SOS), which compensates for encounters with hypoxia that occur during development, disease, and at altitude. Consisting of the resistance pulmonary arteries (PA), ductus arteriosus, carotid body, neuroepithelial body, systemic arteries, fetal adrenomedullary cell and fetoplacental arteries, the SOS optimizes O2-uptake and delivery. Hypoxic pulmonary vasoconstriction (HPV), a vasomotor response of resistance PAs to alveolar hypoxia, optimizes ventilation/perfusion matching and systemic pO2. Though modulated by the endothelium, HPV's core mechanism resides in the smooth muscle cell (SMC). The Redox Theory proposes that HPV results from the coordinated action of a redox sensor (proximal mitochondrial electron transport chain) which generates a diffusible mediator (a reactive O2 species, ROS) that regulates effector proteins (voltage-gated K(v) channels). Hypoxic withdrawal of ROS inhibits K(v)1.5 and K(v)2.1, depolarizes PASMCs, activates voltage-gated Ca2+ channels, increasing Ca2+ influx and causing vasoconstriction. Hypoxia's effect on ROS (decrease vs. increase) and the molecular origins of ROS (mitochondria vs. NADPH oxidase) remains controversial. Distal to this pathway, Rho kinase regulates the contractile apparatus' sensitivity to Ca2+. Also, a role for cADP ribose as a redox-regulated mediator of intracellular Ca2+ release has been proposed. Despite tissue heterogeneity in the SOS's output (vasomotion versus neurosecretion), O2-sensitive K+ channels constitute a conserved effector mechanism. Disorders of the O2-sensing may contribute to diseases, such as pulmonary hypertension.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16686435

Source DB:  PubMed          Journal:  Novartis Found Symp        ISSN: 1528-2511


  8 in total

1.  Apparent PKA activity responds to intermittent hypoxia in bone cells: a redox pathway?

Authors:  Yan-Liang Zhang; Hesam Tavakoli; Mirianas Chachisvilis
Journal:  Am J Physiol Heart Circ Physiol       Date:  2010-05-07       Impact factor: 4.733

Review 2.  The role of mitochondria in pulmonary vascular remodeling.

Authors:  Peter Dromparis; Gopinath Sutendra; Evangelos D Michelakis
Journal:  J Mol Med (Berl)       Date:  2010-08-24       Impact factor: 4.599

3.  SUMO modification regulates inactivation of the voltage-gated potassium channel Kv1.5.

Authors:  Mark D Benson; Qiu-Ju Li; Katherine Kieckhafer; David Dudek; Matthew R Whorton; Roger K Sunahara; Jorge A Iñiguez-Lluhí; Jeffrey R Martens
Journal:  Proc Natl Acad Sci U S A       Date:  2007-01-29       Impact factor: 11.205

Review 4.  Adenosine A₂a receptors and O₂ sensing in development.

Authors:  Brian J Koos
Journal:  Am J Physiol Regul Integr Comp Physiol       Date:  2011-06-15       Impact factor: 3.619

5.  Hypoxia induces voltage-gated K+ (Kv) channel expression in pulmonary arterial smooth muscle cells through hypoxia-inducible factor-1 (HIF-1).

Authors:  Qian Dong; Ning Zhao; Cheng-Kun Xia; Li-li Du; Xiao-Xing Fu; Yi-Mei Du
Journal:  Bosn J Basic Med Sci       Date:  2012-08       Impact factor: 3.363

6.  Superoxide generated at mitochondrial complex III triggers acute responses to hypoxia in the pulmonary circulation.

Authors:  Gregory B Waypa; Jeremy D Marks; Robert D Guzy; Paul T Mungai; Jacqueline M Schriewer; Danijela Dokic; Molly K Ball; Paul T Schumacker
Journal:  Am J Respir Crit Care Med       Date:  2013-01-17       Impact factor: 21.405

Review 7.  O2 sensing, mitochondria and ROS signaling: The fog is lifting.

Authors:  Gregory B Waypa; Kimberly A Smith; Paul T Schumacker
Journal:  Mol Aspects Med       Date:  2016-01-14

Review 8.  The molecular genetics and cellular mechanisms underlying pulmonary arterial hypertension.

Authors:  Rajiv D Machado
Journal:  Scientifica (Cairo)       Date:  2012-12-20
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.